Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jan;86(1):66-117.
doi: 10.1016/j.jinf.2022.09.027. Epub 2022 Sep 30.

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis

Qian Zheng  1 , Pengfei Ma  1 , Mingwei Wang  2 , Yongran Cheng  3 , Mengyun Zhou  4 , Lan Ye  5 , Zhanhui Feng  6 , Chunlin Zhang  7
Affiliations
Meta-Analysis

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis

Qian Zheng et al. J Infect. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors report that they have no potential conflicts of interest.

Figures

Fig 1
Fig. 1
Incidence of rebound (A) and adverse events (B) in Paxlovid group and control group.
Fig 2
Fig. 2
Subgroup analysis: impact of Paxlovid on mortality and hospitalization rates of COVID-19 patients.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Wang Y., Chen X., Xiao W., Zhao D., Feng L. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid. J Infect. 2022 doi: 10.1016/j.jinf.2022.08.012. - DOI - PMC - PubMed
    1. Dryden-Peterson S., Kim A., Kim A.Y., Caniglia E.C., Lennes I., Patel R., Gainer L., Dutton L., Donahue E., Gandhi R.T., Baden L.R., Woolley A.E. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. medRxiv. 2022 doi: 10.1101/2022.06.14.22276393. - DOI - PMC - PubMed
    1. Ganatra S., Dani S.S., Ahmad J., Kumar A., Shah J., Abraham G.M., McQuillen D.P., Wachter R.M., Sax P.E. Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19. Clin Infect Dis. 2022 doi: 10.1093/cid/ciac673. - DOI - PMC - PubMed
    1. Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simon-Campos A., Pypstra R., Rusnak J.M., E.-H. Investigators Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542. - DOI - PMC - PubMed
    1. Hedvat J., Lange N.W., Salerno D.M., DeFilippis E.M., Kovac D., Corbo H., Chen J.K., Choe J.Y., Lee J.H., Anamisis A., Jennings D.L., Codispodo G., Shertel T., Brown R.S., Jr., Pereira M.R. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. Am J Transplant. 2022 doi: 10.1111/ajt.17140. - DOI - PMC - PubMed

Substances